Moderna Reports 29% Year-Over-Year Revenue Growth in Q3
Moderna (MRNA) reported a strong third quarter, generating $1.3 billion in revenue, which represents a 29% increase compared to the previous year. CEO Stéphane Bancel attributed this performance to robust commercial execution during the period. Looking ahead, the company has provided optimistic guidance for 2026, forecasting revenue growth between 15% and 25%. Additionally, Moderna is targeting a year-end cash position of $8.1 billion to $8.3 billion, signaling a focus on maintaining liquidity to support its ongoing development pipeline.
Tickers: $MRNA